Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
| Autor: | Coleman K. Obasaju, H. L. West, Heather A. Wakelee, R. J. Belt, R. Chen, M. C. Perry |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic medicine.medical_specialty Guanine Lung Neoplasms Time Factors medicine.medical_treatment Phases of clinical research Kaplan-Meier Estimate Pemetrexed Neutropenia Deoxycytidine Gastroenterology Disease-Free Survival Drug Administration Schedule Glutamates Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Neoplasm Staging Aged 80 and over Chemotherapy business.industry Hematology Middle Aged medicine.disease Gemcitabine United States Surgery Treatment Outcome Oncology Folic Acid Antagonists Female business Febrile neutropenia Progressive disease medicine.drug |
| Zdroj: | Annals of Oncology. 20:850-856 |
| ISSN: | 0923-7534 |
| Popis: | Background: Previous studies of the gemcitabine-pemetrexed combination in patients with late-stage non-small-cell lung cancer (NSCLC) utilized a 90-min delay between gemcitabine and pemetrexed administration. This phase II study evaluated activity when these agents were administered in rapid succession. Materials and methods: Chemonaive patients with late-stage NSCLC received gemcitabine 1250 mg/m 2 on days 1 and 8, with pemetrexed 500 mg/m 2 immediately following day 8 gemcitabine every 21 days for six cycles, folic acid, B 12, and steroid prophylaxis. Results: Fifty-four enrolled patients (53 treated) completed a median of four cycles. Median dose intensity was 84% (gemcitabine) and 83% (pemetrexed); 68% of patients required dose adjustments. Response was as follows: complete response, 0; partial response, 7 (13%); stable disease, 29 (54%); progressive disease, 9 (17%); and unknown/unavailable, 9 (17%). Median progression-free and overall survival was 4.6 and 12.4 months, respectively. Common grade 3 or 4 toxic effects were as follows: neutropenia (40%); fatigue and dyspnea (21 % each); pneumonia (17%); febrile neutropenia and thrombocytopenia (11 % each); and anemia (6%). Conclusions: The gemcitabine-pemetrexed combination is minimally active in late-stage NSCLC, with a high incidence of grade 3 or 4 toxic effects requiring frequent dose adjustments. A gemcitabine dose |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|